Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Phenotypic shift from primitive to monocytic immunophenotype is unique to patients treated with azacitidine + venetoclax (AZA/VEN) and associated with worse outcomes in AML

Daniel Peters, Diana Abbott, Jingjing Zhang, Jacob Fang, Zenggang Pan, Jeffrey Schowinsky, Jonathan Gutman, Andrew Kent, Mathew Angelos, Christine McMahon, Maria Amaya, Marc Schwartz, Wei Xie, Jonathan Galeotti, Jill Buss, Ann-Kathrin Eisfeld, Curtis Lachowiez, Joshua Zeidner, Daniel Pollyea

Blood (2025) 146 (Supplement 1): 3377.

https://doi.org/10.1182/blood-2025-3377

Published: 2025

Journal Articles

Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions

Blood (2025) 146 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2025-1798

Published: 2025

Journal Articles

County-level analysis reveals two high-incidence regions and potential environmental contributors to myeloid malignancies in Colorado

Jason Gilbert, Diana Abbott, Elizabeth Molina Kuna, Marcelo Perraillon, Anand Patel, Daniel Pollyea

Blood (2025) 146 (Supplement 1): 2853.

https://doi.org/10.1182/blood-2025-2853

Published: 2025

Journal Articles

Tri-partied analyses define clinical outcomes and molecular features of patients (pts) with acute promyelocytic leukemia (APL)

Blood (2025) 146 (Supplement 1): 8183.

https://doi.org/10.1182/blood-2025-8183

Published: 2025

Journal Articles

Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts

Blood (2024) 144 (Supplement 1): 1828.

https://doi.org/10.1182/blood-2024-199336

Published: 2024

Journal Articles

Treatment-Related and De Novo Ccus Have Similar Molecular Features and Risk of Progression to Myeloid Malignancies

Jennifer Santos, Diana Abbott, Grace Bosma, Andrew Kent, Marc Schwartz, Christine M. McMahon, Jonathan Gutman, Daniel A Pollyea, Maria L Amaya

Blood (2024) 144 (Supplement 1): 5649.

https://doi.org/10.1182/blood-2024-201062

Published: 2024

Journal Articles

Efficacy and Molecular Predictors of Response and Survival for Venetoclax/Azacitidine Therapy in Relapsed or Refractory Acute Myeloid Leukemia

Jason S. Gilbert, Megan Connor, Grace Bosma, Christine M. McMahon, Maria L Amaya, Jonathan Gutman, Marc Schwartz, Andrew Kent, Diana Abbott, Daniel A Pollyea

Blood (2024) 144 (Supplement 1): 4266.

https://doi.org/10.1182/blood-2024-199862

Published: 2024

Journal Articles

Access to Novel Therapies Impacts Overall Survival (OS) in Low Socioeconomic (SES) Acute Myeloid Leukemia (AML) Patients (Pts)

Cassandra Duarte, Diana Abbott, Christine M. McMahon, Andrew Kent, Marc Schwartz, Jonathan Gutman, Daniel A Pollyea, Maria L Amaya

Blood (2024) 144 (Supplement 1): 3803.

https://doi.org/10.1182/blood-2024-201061

Published: 2024

Journal Articles

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Blood (2024) 144 (Supplement 1): 6451.

https://doi.org/10.1182/blood-2024-194844

Published: 2024

Journal Articles

Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy

Blood (2024) 144 (Supplement 1): 969.

https://doi.org/10.1182/blood-2024-199267

Published: 2024

Journal Articles

Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia

Maria L Amaya, Christine M. McMahon, Marc Schwartz, Jonathan Gutman, Andrew Kent, Diana Abbott, Connor Sohalski, Jessica Dell-Martin, Ayele Belachew, Brett M Stevens, Craig T Jordan, Daniel A Pollyea

Blood (2024) 144 (Supplement 1): 4259.

https://doi.org/10.1182/blood-2024-202839

Published: 2024

Journal Articles

Socioeconomic Status Is a Mediator of Overall Survival in Acute Myeloid Leukemia (AML)

Cassandra Duarte, Diana Abbott, Grace N Bosma, Christine M. McMahon, Jonathan A Gutman, Marc Schwartz, Daniel Pollyea, Maria L Amaya

Blood (2023) 142 (Supplement 1): 5176.

https://doi.org/10.1182/blood-2023-174996

Published: 2023

Journal Articles

A Qualitative Study Comparing the Patient and Provider Experience in an Academic Blood Disorder Center

Hunter Tolison, Cassandra Duarte, Glen Peterson, Grace N Bosma, Diana Abbott, Gemlyn George, Daniel Pollyea, Craig T. Jordan, Maria L Amaya

Blood (2023) 142 (Supplement 1): 3688.

https://doi.org/10.1182/blood-2023-179669

Published: 2023

Journal Articles

Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy

Steven M. Bair, Mayur Narkhede, Zachary AK Frosch, Elise A. Chong, Daniel A. Ermann, Iris Isufi, Farrukh T. Awan, Julio C Chavez, Grace N Bosma, Diana Abbott

Blood (2023) 142 (Supplement 1): 68.

https://doi.org/10.1182/blood-2023-187113

Published: 2023

Journal Articles

Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study

Blood (2022) 140 (Supplement 1): 3275–3276.

https://doi.org/10.1182/blood-2022-157802

Published: 2022

Journal Articles

Clinical and Molecular Features of Highly Durable Response to Azacitidine+Venetoclax in Acute Myeloid Leukemia

Alexander Hayden, Grace Bosma, Jonathan A. Gutman, Maria L. Amaya, Diana Abbott, Clayton Smith, Brett M. Stevens, Craig T. Jordan, Daniel A. Pollyea, Christine M. McMahon

Blood (2022) 140 (Supplement 1): 9163–9164.

https://doi.org/10.1182/blood-2022-171064

Published: 2022

Journal Articles

Results from a Phase I Trial Using Nivolumab in Combination with Dose Adjusted EPOCH in Newly Diagnosed Peripheral T-Cell Lymphomas

Bradley M. Haverkos, Jasmine Zain, Manali K. Kamdar, Alexander Neuwelt, Eduardo Davila, Xander Bradeen, Steven M. Bair, Jagar Jasem, Emily Berens, Clayton Smith, Diana Abbott, Pierluigi Porcu

Blood (2022) 140 (Supplement 1): 2308–2309.

https://doi.org/10.1182/blood-2022-168979

Published: 2022

Journal Articles

Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine+Venetoclax in Acute Myeloid Leukemia

Christine M. McMahon, Kellen Gil, Maria L. Amaya, Jonathan A. Gutman, Alexander Hayden, Marc Schwartz, Grace Bosma, Diana Abbott, Brett M. Stevens, Clayton Smith, Craig T Jordan, Daniel A. Pollyea

Blood (2022) 140 (Supplement 1): 6185–6186.

https://doi.org/10.1182/blood-2022-170168

Published: 2022

Journal Articles

Overall Survival and Its Interplay with Allogeneic Stem Cell Transplant and Age in Newly Diagnosed AML Patients Treated with Ven/Aza

Diana Abbott, Grace Bosma, Christine M. McMahon, Marc Schwartz, Jonathan A. Gutman, Daniel A. Pollyea

Blood (2022) 140 (Supplement 1): 6181–6182.

https://doi.org/10.1182/blood-2022-169026

Published: 2022

Journal Articles

A Pilot Study Using Nivolumab in Combination with Standard of Care Chemotherapy in Newly Diagnosed Peripheral T-Cell Lymphomas

Brad Haverkos, Jasmine Zain, Manali Kamdar, Alexander Neuwelt, Steven M. Bair, Jagar Jasem, Emily Berens, Clayton Smith, Diana Abbott, Pierluigi Porcu

Blood (2021) 138 (Supplement 1): 2444.

https://doi.org/10.1182/blood-2021-152617

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phenotypic shift from primitive to monocytic immunophenotype is unique to patients treated with azacitidine + venetoclax (AZA/VEN) and associated with worse outcomes in AML

Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions

County-level analysis reveals two high-incidence regions and potential environmental contributors to myeloid malignancies in Colorado

Tri-partied analyses define clinical outcomes and molecular features of patients (pts) with acute promyelocytic leukemia (APL)

Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts

Treatment-Related and De Novo Ccus Have Similar Molecular Features and Risk of Progression to Myeloid Malignancies

Efficacy and Molecular Predictors of Response and Survival for Venetoclax/Azacitidine Therapy in Relapsed or Refractory Acute Myeloid Leukemia

Access to Novel Therapies Impacts Overall Survival (OS) in Low Socioeconomic (SES) Acute Myeloid Leukemia (AML) Patients (Pts)

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy

Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia

Socioeconomic Status Is a Mediator of Overall Survival in Acute Myeloid Leukemia (AML)

A Qualitative Study Comparing the Patient and Provider Experience in an Academic Blood Disorder Center

Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy

Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study

Clinical and Molecular Features of Highly Durable Response to Azacitidine+Venetoclax in Acute Myeloid Leukemia

Results from a Phase I Trial Using Nivolumab in Combination with Dose Adjusted EPOCH in Newly Diagnosed Peripheral T-Cell Lymphomas

Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine+Venetoclax in Acute Myeloid Leukemia

Overall Survival and Its Interplay with Allogeneic Stem Cell Transplant and Age in Newly Diagnosed AML Patients Treated with Ven/Aza

A Pilot Study Using Nivolumab in Combination with Standard of Care Chemotherapy in Newly Diagnosed Peripheral T-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only